MT-2

MT-2 (Melanotan II) Nasal Spray is supplied by PeptaGen Labs as a catalogued research material in the format and strength: nasal spray, 10mg/10ml. This catalogue designation identifies the presentation; it does not establish analytical content, formulation characteristics or suitability for a particular experimental system.

MT-2/Melanotan II is a defined cyclic lactam peptide and melanocortin analogue, rather than a linear peptide of the Melanotan I/afamelanotide type. Its molecular identity depends on the specified sequence, ring connectivity, stereochemistry and terminal modifications. The formula and molecular mass below describe the non-salt molecular entity, not the complete spray formulation.

Chemical properties and registry information

Registry identifiers describe the specified molecular entity. They do not independently identify excipients, establish the composition of the finished formulation or confirm the identity of a catalogue batch.

Research background and published evidence

Published research

Melanotan II was developed as a conformationally constrained melanocortin analogue. Published work includes cyclic α-MSH analogue design and receptor-binding, signalling and structure–activity research. This literature concerns relationships between peptide structure and melanocortin receptor interactions. It provides background for investigating the compound, rather than analytical evidence for this nasal spray presentation.

Current scientific understanding

Interpretation of melanocortin research depends on the molecular form, experimental model, assay conditions and material evaluated. Findings for a defined reference peptide do not establish equivalent behaviour in a formulated catalogue product. Receptor-level observations also do not establish clinical outcomes or suitability for human or veterinary use. Melanotan II is not an authorized medicinal product.

Formulation note

Published research has mostly used other research materials or routes rather than this nasal spray formulation. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. The vehicle, excipients, peptide content and formulation-specific stability require their own supporting documentation; none should be inferred from the compound name, registry entry or nominal catalogue strength.

Quality and testing

Quality information must be supported by a batch-specific certificate of analysis (CoA) linked to this exact product, presentation and lot. A report for an unformulated peptide, another strength or another batch does not establish the characteristics of this material. The matching SDS should be consulted alongside the CoA for documented composition and material-specific information.

Identity, chromatographic area purity, peptide content, degradation products, microbiological quality and excipient composition are distinct analytical questions. A result for one does not establish the others. Only measurements explicitly documented in the matching report should be regarded as available; absent results must not be interpreted as confirmation of a specification.

For laboratory research use only by qualified professionals. Not for human or veterinary use. No dosing directions are provided. Purchasers are responsible for compliance with applicable requirements.